Andere talen BioArctic AB

Aandelen

BIOA B

SE0010323311

Beurs gesloten - Nasdaq Stockholm Andere beurzen 17:29:57 31-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
242,6 ^SEK	+7,35%		+1,76%	-9,41%

24/05	BioArctic, Eisai's medicijn tegen Alzheimer krijgt goedkeuring in Zuid-Korea	MT
24/05	BioArctic AB (publ) keurt Leqembi [®] goed voor de behandeling van de ziekte van Alzheimer in Zuid-Korea	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

BioArctic, Eisai's Azlheimer’s Disease Drug Wins Regulatory Nod in South Korea	24/05
BioArctic AB Approves Leqembi [®] for the Treatment of Alzheimer's Disease in South Korea	24/05
Transcript : BioArctic AB, Q1 2024 Earnings Call, May 17, 2024	17/05
BioArctic AB Reports Earnings Results for the First Quarter Ended March 31, 2024	17/05
BioArctic, Eisai Launch Rolling US FDA Application for Leqembi's Maintenance Dosing	15/05
BioArctic AB and Eisai Co., Ltd. Sign Research Evaluation Agreement Regarding BAN2802	20/04
BioArctic, Eisai Seek US FDA Approval for Maintenance Dose of Alzheimer’s Disease Drug	01/04
BioArctic Flags Delay in EU Health Regulator's Evaluation of Azlheimer’s Disease Drug	22/03
BioArctic AB and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders	11/03
Transcript : BioArctic AB, Q4 2023 Earnings Call, Feb 14, 2024	14/02
BioArctic AB Reports Earnings Results for the Full Year Ended December 31, 2023	14/02
BioArctic AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14/02
Eisai expects 1,500 Alzheimer's patients in China launch, sees 'huge' growth	05/02
European Medicines Regulator to Discuss Marketing Authorization for BioArctic's Alzheimer's Disease Drug	11/01
The European Medicines Agency's Scientific Advisory Group to Discuss the Marketing Authorisation Application for lecanemab	11/01
BioArctic's Partner Obtains Marketing Authorization for Leqembi in China	09/01
Leqembi® Approves for the Treatment of Alzheimer's Disease in China	09/01
BioArctic, Eisai Sets Launch Date for Alzheimer’s Disease Drug in Japan	13/12
Transcript : BioArctic AB, Q3 2023 Earnings Call, Nov 08, 2023	08/11
BioArctic AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen BioArctic AB

Aandelen

BIOA B

SE0010323311

Andere talen

Filters